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Background (219/200 words) 
Travellers’ diarrhoea (TD) is a common health problem among visitors to the (sub)tropics. Much research 
deals with aetiology, prevention, and post-infection sequalae, yet the data may not allow comparisons due to 
incompatible definitions of TD and No TD control groups.  
 
Method 
The impact of defining TD and No TD control groups was explored by revisiting our recent data. We set up 
two TD groups: classical TD i.e. ≥3 loose or liquid stools/day and WHO TD (diarrhoea as defined by the 
WHO) i.e. any diarrhoea, and four No TD groups by TD definition and timing (no classical/WHO TD during 
travel, no ongoing classical/WHO TD). 
 
Results  
TD was recorded for 37% versus 65% of subjects when using classical versus WHO definitions, 
respectively; the proportions of the various pathogens proved similar. The strictest criterion for theNo TD 
control group (no WHO TD during travel) yielded pathogens among 61% and the least strict (no ongoing 
classical TD) among 73% of the travellers; the differences were greatest for enteroaggregative Escherichia 
coli and Campylobacter. 
 
Conclusions 
Definition of TD and control group design substantilly impact on TD study results. The WHO definition 
yields more cases, but the pathogen selection is similar by both definitions. Design of the No TD control 

















1. INTRODUCTION    
Travellers’ diarrhoea (TD) is contracted by 10–40% of travellers to middle- or low-income 
countries [1]. A great deal of research has been conducted on its aetiology [1-19], prevention, risk factors 
[20-22] and associated consequences, such as acquisition of multiresistant Enterobacteriaceae [23-29] and 
development of post-infectious irritable bowel syndrome [30-35]. The results of the various studies may, 
however, not be comparable due to variation in defining TD and determining control groups; some 
aetiological studies even lack control groups. [6,7,9,11,15,16] 
New molecular methods offer better coverage of pathogens [12,15,36,37] thus decreasing the 
proportion of TD cases with unknown aetiology in various studies from almost half of the travellers 
[1,8,10,13] to as low as 5–24% [11,12,14,18,19]. 
Many studies have applied the definition of classical TD, i.e. the passage of three or more 
watery or loose stools per day with or without one r more of the accompanying symptoms (nausea, 
abdominal pain, vomiting) (below referred to as classical TD, Figure 1) [5]. The WHO, however, defines 
diarrhoea as the passage of three or more loose or liquid stools per day or, alternatively, more frequntly than 
is normal for the individual [38] (below referred to as the WHO TD, Figure 1). While the definitions overlap 
with respect to moderate and most severe cases, the WHO definition covers a large group of cases (24–39% 
of all) not included in the classical definition at all: those with a mild clinical picture [5,14,18,39 40]. It 
should be noted that bacterial findings have generally been found similar between travellers with mild and 
moderate/severe symptoms [7,16,18]. 
Studies applying PCR- and culture-based methods have revealed diarrhoeal pathogens in 9–
45% of the travellers without TD [3,4,10,12-14,17-19,41]. Pathogen findings in asymptomatic individuals 
have been suggested to reflect the high sensitivity of new methods to detect low numbers of bacteria, 
continuing excretion of pathogens in travellers with resolved symptoms, weaker pathogenicity of the strains 
and/or host immunity [42]. Conversely, in some studies, the definition of the No TD control group has failed 
to exclude travellers with mild TD [2,10,12,17,19,41] or resolved symptoms, [10,12,13,17,41]; even 















pathogens to be associated with TD but provide no data on control groups should be confirmed by further 
research [9]. 
We sought to understand the impact of TD definitions a d accurate control groups on the 
results of the TD studies. To this end, we investigated the TD and No TD definitions by reanalysing the data 
of our previous study of 382 Finnish travellers with no antimicrobial use during travel. We chose to focus on 
findings with enteroaggregative (EAEC), enteropathogenic (EPEC), and enterotoxigenic (ETEC) 
Escherichia coli, and Campylobacter jejuni/coli, as these pathogens were associated with TD symptoms in 
our previous report [18].  


















 2. METHODS  
2.1. Study population 
We reanalysed our recent data [18] on pathogen findings of 382 travellers who had not 
used antibiotics during their journey. They had provided pre- and post-travel stool samples and completed 
questionnaires before and after travel. Recruitment of volunteers, handling of stool specimens, and 
identification of bacterial pathogens were detailed n our previous reports [18,36]. The study protocol was 
approved by the Ethics Committee of the Helsinki University Hospital. All participants had given written 
informed consent. For the same volunteers, we previously reported the findings of resistant 
Enterobacteriacae [24,28], travel-related health problems [43], stool pathogen findings in various 
geographical regions [44] as well as of those 382 travellers who used no antimicrobials [18]. 
 
2.2. Definitions of TD and No TD  
For the presence/absence of TD symptoms, the travellers were classified in three categories: 
Asymptomatic (no diarrhoea during travel), resolved TD (no TD at the time of sampling but TD during the 
journey), and ongoing TD (ongoing TD at the time of sampling) (Figure 1).  
The severity of TD was classified as mild if it comprised one or two loose or liquid stools per 
day without high fever or blood in stools, and moderat /severe with three or more diarrhoeal stools. The 
classical TD definition covered those with moderate/severe TD, but not those with mild TD; the WHO TD 
definition covered all cases with diarrhoea (Figure 1). 
The possible impact on the pathogen findings resulting from the use of various TD and No TD 
definitions was approached by forming one group for each TD definition (classical versus WHO TD), and 
four groups for the No TD definitions (no ongoing classical TD, no classical TD during travel, no ongoing 
WHO TD, and no WHO TD during travel, Figures 1, 2, and 3). Assignment to group depended on whether 
travellers with resolved symptoms were included (no o going versus no TD during travel) and whether mild 
















2.4. Statistical analysis 
For categorical variables, statistical analyses were ca ried out with Chi-square tests, Fisher’s 
exact test, or binary logistic regression analysis when applicable. The binominal regression model was used 
in order to obtain profile likelihood confidence intervals. Statistical significance was defined as p<0.05 or 
when confidence intervals did not overlap. The statistical analysis was conducted using SPSS 22 software 


















3. RESULTS   
3.1. Traveller demographics, itineraries, and pathogen findings  
This study comprised 382 volunteers who had not taken antimicrobials during travel outside 
Nordic countries. Demographic and travel data have been described in detail in our previous article [18]. In 
brief, 233 (61%) travellers were women and 149 (39%) men. The median age was 36 years (IQR 27), and the 
median duration of travel was 16 days (IQR 10). Themost popular destination was Sub-Saharan Africa (171
travellers; 45%), followed by South East Asia (91; 25%), South Asia (52; 14%), and Latin America (36; 
9%).  
The results of the PCR analyses for pathogens have been reported earlier [18]. In brief, a 
bacterial pathogen was detected in 75% of post-travel samples: EPEC (46%) and EAEC (45%) were the 
most common findings, followed by ETEC (20%), and Campylobacter (7%). Multiple pathogens were found 
in 40% of post-travel samples. 
 
3.2. Proportions of travellers with TD by classical or WHO criteria 
The difference between the two TD definitions concer s those with mild symptoms: they are 
defined as TD cases only when the WHO definition is used (Table 1). In the present data, 107/242 (44%) 
travellers in our study population had mild TD (onging or resolved). Diarrhoeal symptoms experienced 
during travel or immediately after return were classified as TD for 140 (37%) cases if the classical TD 
criteria were used, and for 247 (65%) if applying the WHO criteria. At the time of post-travel stool sampling, 
73 (19%) had ongoing TD by classical and 115 (30%) by WHO criteria, and among 67 (18%) and 132 (35%) 
the symptoms had already resolved, respectively. 
 
3.3. Comparison of pathogen findings when using classical and WHO TD definitions  
For ongoing TD, the proportions of pathogens proved similar regardless of the TD definition 















(84%) stool samples, EPEC in 41 (56%), EAEC in 39 (53%), ETEC in 31 (42%), and Campylobacter in 6 
(8%). The respective figures with the WHO criteria gave one or more bacterial pathogens in 96 (83%) stool
samples, EPEC in 63 (55%), EAEC in 58 (50%), ETEC in 42 (37%), and Campylobacter in 9 (8%).  
Likewise, for those with resolved symptoms, the findings were similar with both TD 
definitions (classical and WHO) (Table 1). In contrast, when compared to those with ongoing TD, the 
proportions of EPEC and ETEC were lower among travellers with resolved, compared to ongoing symptoms 
with both definitions, whereas for EAEC and Campylobacter, the difference was not significant. 
 
3.4. Proportions of travellers in No TD control groups 
 When No TD was defined as no ongoing TD symptoms at the time of post-travel stool 
sampling (but possibly during travel), 309 (81%) and 267 (70%) travellers were categorised into the control 
group according to the classical and WHO criteria, respectively.  
When travellers with resolved symptoms were excluded from the No TD control groups, the 
classical criteria yielded 242 TD cases (63%; no classical TD during travel) and, if also excluding those with 
mild symptoms, i.e. using the WHO criteria (no WHO TD during travel), gave 135 (35%) cases as No TD. 
 
3.5. Comparison of bacterial findings with different definitions for No TD control group  
If the No TD control group was described as no ongoing TD at the ime of sampling, a 
pathogen was detected in 73% (95% CI 68-78%) and 72% (66-77%) of cases by the classical and WHO TD 
criteria; Campylobacter was found in 7% (4-10%) and 6% (4-10%), and EAEC in 43% (37-48%) and 42% 
(36-48%) of cases, respectively.  
If the No TD control group was defined as no TD during travel, the proportion of travellers 
with positive pathogen findings was 70% (64-77%) versus 61% (52-69%) when using the classical versus 
WHO definitions, respectively; Campylobacter was found in 4% (2-7%) and 1% (95% CI 0-3%), and EAEC 
















3.6. Impact of No TD definitions on the interpretation of causative agents for TD 
The No TD definition used had an impact on the interpretation of the role of each pathogen as 
causative agent of TD (Table 1): when no classical TD during travel was chosen as the No TD control group, 
travellers with ongoing symptoms did not differ from controls with respect to EPEC and Campylobacter 
findings. When travellers with resolved symptoms were included in the control groups (no ongoing classical 
or WHO TD), no significant differences were found for EAEC and Campylobacter.  
When the No TD control group comprised only travellers without any diarrhoeal symptoms 
during the journey (no WHO TD during travel), EPEC, EAEC, ETEC, and Campylobacter were all 















4. DISCUSSION  
Diarrhoea remains the most common reason for travellers to contact health care both when on 
a journey and after their return [43,45-47]. The aetiology and consequences of TD have been widely studied, 
but the comparability and even reliability of various studies may have been jeopardized by incompatible 
definitions used for TD and No TD control groups. We scrutinised these differences by revisiting the 
findings of our aetiological study and comparing the results obtained when applying the differing criteria.  
 
4.1. Definition of TD: classical versus WHO  
The major difference between the two definitions (classical and WHO) concerns cases with 
mild diarrhoea: these are included in the WHO definitio , while the classical criteria only denote cases with 
three or more unformed stools with or without additional symptoms. The population with mild symptoms 
was substantial, 44% of all subjects. This indicates  significant effect on the number of TD cases: they were 
recorded by 37% versus 65% when evaluating by the classi al versus WHO criteria, respectively. Indeed, the 
definition of TD is evidently reflected in the number of cases recorded. Comparing TD risk between various 
regions is valid only when using the same TD definitio . For this reason, we suggest that when analysing TD 
rates, the results should be reported according to both (classical and WHO) definitions. 
 
4.2. Pathogen findings among travellers with ongoing TD 
Travellers with milder symptoms are in many studies excluded from subject groups [15,48] or 
included in the No TD group [10,13]. Findings among such subjects with mild symptoms are only described 
in a few papers [5,7]. Our previous report on the same travellers [18], however, did not show significant 
differences between those with mild symptoms and those with moderate or severe symptoms in the 
pathogens detected, a finding consistent with the studies by Jiang et al [7] and Frickmann et al [16]. With 
respect to pathogen findings of EPEC, EAEC, ETEC, and Campylobacter, both definitions (classical and 















We recommend that studies of the aetiology of TD use the WHO definition to ensure that the 
No TD group is fully asymptomatic. On the other hand, as antibiotics should only be considered for severe 
diarrhoea, the classical definition appears reasonable for studies comparing various antibiotics. This also 
applies to research exploring preventive strategies: th  definition should be made according to purpose 
(which degree of severity prevention is aimed at). Also in such studies, recording milder symptoms would 
enable subgroup analyses of the various cases. 
 
4.3. Pathogen findings among travellers with resolved symptoms  
We scrutinized separately travellers with resolved TD because in some studies they have been 
categorised into TD and in others into no ongoing TD groups. Our results suggest that if travellers with 
resolved TD are included in the TD group, the propotions of EPEC and ETEC will be underestimated. By 
contrast, the results of the comparison between those with resolved symptoms with the controls (no TD 
during travel) depended of by TD criteria used: when we applied the classical criteria, ETEC and 
Campylobacter proved more prevalent among travellers with resolved symptoms than in the control group; 
when we applied the WHO criteria the difference wassignificant for EAEC and Campylobacter. It thus 
appears that certain pathogens are found in the stools after the symptoms have resolved, a finding consistent 
with extended excretion of nontyphoidal Salmonella [49] and Campylobacter jejuni [50] for weeks after 
recovery from clinical illness. Diarrhoeagenic Escherichia coli have also been found in faecal samples after 
the resolution of symptoms [18,41]: in the research by Adachi et al [41], the proportion of travellers with 
EAEC increased over the four study weeks. Indeed, the findings of travellers with diarrhoea during any time 
of travel should be analysed separately from those asymptomatic throughout the journey, irrespective of time 
elapsed between resolution of symptoms and stool sampling.  
  
4.4. Pathogen findings among four different No TD control groups  
The main point where the definitions of No TD groups differ concerns inclusion of travellers 















symptoms throughout the journey (no WHO TD during travel), a pathogen was detected in the stool samples 
of 61% of the travellers. By contrast, if No TD was defined by the least strict definition, i.e. not having 
ongoing moderate/severe diarrhoea (no ongoing classi al TD) at the time of sampling, 73% of the travellers 
had one or more pathogens; the respective figures were 28% and 43% for EAEC, and 1% and 7% for 
Campylobacter. As the pathogen findings between the No TD groups differ substantially by definition, we 
recommend that the composition of the control groups should be described in greater detail in future studies. 
 
4.5. Possible impact of No TD definitions on results of aetiological studies of TD  
The definition of TD and control group design were also reflected in the evaluation of the role 
of the pathogens causing the symptoms. Had the TD group in our study been defined as ‘ongoing classic l 
TD’ and the No TD group as ‘no classical TD during travel' (i.e. those with ongoing and resolved mild 
symptoms included in control group) (Table 1), no difference would have been found in the EPEC and 
Campylobacter rates. If, on the other hand, travellers with resolved symptoms (either classical or WHO) had 
been included in the No TD control group, EAEC and Campylobacter would not have been observed as 
significant pathogens. In contrast, when the No TD control group comprised only travellers without any 
diarrhoeal symptoms (not even mild ones) during the journey, all four pathogens appeared significant. These 
examples may partly explain the differing results in tudies analysing the role of some pathogens, for 
example EAEC [3,51] and EPEC [3,10] in causing TD. Hence, the role of various pathogens should only be 
evaluated in study settings with a No TD control group comprising those fully asymptomatic (not showing 
even mild symptoms) during the journey. 
 
4.6. Limitations 
The stool samples were collected only after return, thus allowing new bacteria to possibly 
colonize the intestine in cases with resolved TD and, likewise, some pathogens to disappear; ETEC, for 
example, is known to vanish rather quickly [18,41,52]. As for the limitations of the PCR method per se, th y 

















Our data imply that specifying No TD is at least equally important as defining TD. This 
applies not only to studies of the aetiology of TD but most likely also to those presenting risk factor analyses 
or evaluations of post-infection sequelae, such as irritable bowel syndrome or colonization with 
multiresistant Enterobacteriaceae. The classical and WHO definition of TD yielded identical selections of 
pathogens, a finding suggesting that the criteria for TD can be chosen according to focus of study. However, 
further attention should be paid to N  TD control group design and findings among travellers with resolved 
TD symptoms: No TD groups should only consist of travellers who have not shown any gastrointestinal 
symptoms throughout the journey.  
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Figure 2. Definitions of TD and No TD when applying classical criteria for TD 
 
 





























Table 1. Findings of EPEC, EAEC, ETEC, and Campylobacter in relation to TD symptoms among 382 
travellers not having taken antibiotics during their journey.  The findings are presented separately for TD 
defined by classical and WHO criteria, and whether TD was ongoing, resolved, or absent. Statistical 
comparisons are given for the various TD and No TD definitions, the data showing the significance of 
definitions and the apparent role of EPEC, EAEC, ETEC, and Campylobacter as causative agents for TD. 
 
  All travellers 
Any bacterial 
pathogen 
EPEC EAEC ETEC Campylobacter 


















 382  287 (75)  174 (46)  171 (45)  76 (20)  26 (7)  
Ongoing TD 
Classical TD definition 73 (19) 15-23 61 (84) 74-91 41 (56) 45–67 39 (53) 42–65 31 (42) 32–54 6 (8) 3–16 
WHO TD definition 115 (30) 26-35 96 (83) 76–90 63 (55) 46–64 58 (50) 41–60 42 (37) 28–46 9 (8) 4–14 
No ongoing TD symptoms at the time of stool sampling 
-TD resolved 
Classical TD definition 67 (18) 14-22 56 (84) 74–91 25 (37) 26-49 42 (63) 51-74 12 (18) 10-28 10 (15) 8-25 
WHO TD definition 132 (35) 30-39 109 (83) 76-88 54 (41) 33-49 75 (57) 48-65 22 (17) 11-24 16 (12) 7-18 
-No ongoing TD control group 
Classical TD definition 309 (81) 77-85 226 (73) 68–78 133 (43) 38–49 132 (43) 37–48 45 (15) 11–19 20 (7) 4–10 
WHO TD definition 267 (70) 65-74 191 (72) 66–77 111 (42) 36–47 113 (42) 36–48 34 (13) 9–17 17 (6) 4–10 
-No TD during travel control group 
Classical TD definition 242 (63) 58-68 170 (70) 64–77 108 (45) 38–51 90 (37) 31–43 33 (14) 10–18 10 (4) 2–7 
WHO TD definition 135 (35) 31-40 82 (61) 52–69 57 (42) 34–51 38 (28) 21–36 12 (9) 9–14 1 (1) 0–3 
Univariate statistics for Classical TD definition 
Classical TD ongoing vs. No 
Classical TD ongoing 
OR (95% CI) 1.9 (1.0-3.6) 1.7 (1.0-2.8) 1.5 (0.9-2.6) 4.3 (2.5-7.6) 1.3 (0.5-3.3) 
P 0.064 0.043 0.098 <0.001 0.606 
Classical TD ongoing vs. No 
Classical TD during travel 
OR (95% CI) 2.2 (1.1-4.2) 1.6 (0.9-2.7) 1.9 (1.1-3.3) 4.7 (2.6-5.4) 2.1 (0.7-5.9) 
P 0,027 0,085 0,014 <0.001 0,171 
Classical TD resolved vs. 
No Classical TD during 
travel 
OR (95% CI) 2.2 (1.1-4.4) 0.7 (0.4-1.3) 2.8 (1.6-5.0) 1.4 (0.7-2.9) 4.0 (1.6-10.2) 
P 0,032 0,286 <0.001 0,382 0,003 
Classical TD resolved vs. 
Classical TD ongoing 
OR (95% CI) 1.0 (0.4-2.5) 0.5 (0.2-0.9) 1.5 (0.7-2.9) 0.3 (0.1-0.6) 2.0 (0.7-5.7) 
P 0.997 0.026 0.268 0.002 0.213 
Univariate statistics for WHO TD definition  
WHO TD ongoing vs  
no WHO TD during travel 
OR (95% CI) 3.3 (1.8-6.0) 1.7 (1.0-2.7) 2.6 (1.5-4.4) 5.9 (2.9-11.9) 11.4 (1.4-91.2) 
P <0.001 0.048 <0.001 <0.001 0.022 
WHO TD ongoing vs  
no WHO TD ongoing 
OR (95% CI) 2.0 (1.1-3.5) 1.7 (1.1-2.6) 1.4 (0.9-2.2) 3.9 (2.3-6.7) 1.2 (0.5-2.9) 
P 0,013 0,017 0,144 <0,001 0,603 
WHO TD resolved vs.  
no WHO TD during travel 
OR (95% CI) 3.1 (1.7-5.4) 0.9 (0.6-1.5) 3.4 (2.0-5.6) 2.1 (1.0-4.3) 18.5 (2.4-141.5) 















WHO TD resolved vs. 
WHO TD ongoing 
OR (95% CI) 0.9 (0.5-1.8) 0.6 (0.3-0.9) 1.3 (0.8-2.1) 0.4 (0.2-0.6) 1.6 (0.7-3.8) 
P 0.851 0.030 0.316 <0.001 0.286 
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